PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Participate in the 4th Annual Guggenheim Boston Healthcare Conference

GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the 4th Annual Guggenheim Boston Healthcare Conference.

Conference details are as follows:

Date: Tuesday, December 13, 2016
Location: Intercontinental Boston Hotel, Boston, MA

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:

Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations

ir@novavax.com 
240-268-2000
              
Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271

Primary Logo

Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept